Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical is a clinical-stage oncology therapeutics company with a promising and unique technology, Alpha DaRT, which utilizes alpha particles for localized radiation therapy. The company has a strong pipeline targeting different tumor types and has multiple ongoing clinical trials in the U.S., which could potentially lead to commercial success. Its strong cash position and potential approval in Japan add to the positive outlook for the company. However, risks such as failure in clinical trials and competition should be considered.

Bears say

Alpha Tau Medical is showing promise in its innovative Alpha DaRT technology for treating various types of cancers. However, the company's reliance on a single product and limited revenue sources from only a few countries may pose significant financial risks. Additionally, the FDA's Breakthrough Device designation for Alpha DaRT is not a guarantee of regulatory approval, and the modular PMA submission process could lead to delays and uncertainties, further adding to the company's potential risks.

DRTS has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Buy based on their latest research and market trends.

According to 3 analysts, DRTS has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.